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ABSTRACT
Glioblastoma (GBM) stem cells (GSCs) reside in both hypoxic and vascular 
microenvironments within tumors. The molecular mechanisms that allow GSCs to 
occupy such contrasting niches are not understood. We used patient-derived GBM 
cultures to identify GSC subtypes with differential activation of Notch signaling, 
which co-exist in tumors but occupy distinct niches and match their metabolism 
accordingly. Multipotent GSCs with Notch pathway activation reside in perivascular 
niches, and are unable to entrain anaerobic glycolysis during hypoxia. In contrast, 
most CD133-expressing GSCs do not depend on canonical Notch signaling, populate 
tumors regardless of local vascularity and selectively utilize anaerobic glycolysis 
to expand in hypoxia. Ectopic activation of Notch signaling in CD133-expressing 
GSCs is sufficient to suppress anaerobic glycolysis and resistance to hypoxia. These 
findings demonstrate a novel role for Notch signaling in regulating GSC metabolism 
and suggest intratumoral GSC heterogeneity ensures metabolic adaptations to support 
tumor growth in diverse tumor microenvironments.
INTRODUCTION
Glioblastoma (GBM) is the most common primary 
brain malignancy (http://www.cbtrus.org). Despite 
surgery and chemoradiotherapy, prognosis remains poor 
[1-3]. GBM growth is maintained by a dynamic cellular 
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hierarchy dominated by GBM stem cells (GSCs) [4-10]. 
Due to their inherent resistance to current therapies, GSCs 
represent crucial therapeutic targets [9-11]. 
A major challenge in GBM is its inter- [12, 13] and 
intra-tumoral [14-16] heterogeneity. In particular, GBM’s 
microenvironmental heterogeneity is highlighted by areas 
of microvascular proliferation interspersed with hypoxic 
regions of pseudopalisading necrosis (PPN) [17]. Both 
microenvironments harbor GSCs [18-27]. The differences 
in vascularity and oxygen tension between these niches 
suggest distinct molecular mechanisms regulating GSC 
self-renewal and metabolism. However, these mechanisms 
are not understood.
The Notch signaling pathway, critical for neural 
stem cell (NSC) self-renewal and differentiation [28-
31], also regulates GSC self-renewal, tumorigenicity, 
radioresistance and differentiation into vascular lineages 
[6, 32-36]. Upon binding the Delta or Jagged families of 
ligands, the Notch receptor is cleaved by γ-secretase [31]. 
Cleaved Notch intracellular domain (NICD) translocates 
to the nucleus, where it forms a complex with RBPJ 
and MAML to activate transcription of HES and HEY 
genes, which maintain multipotency [29-31]. Tumor 
endothelium provides Notch ligands, which support GSC 
self-renewal in the perivascular niche [18, 37-40], similar 
to NSCs [41-43]. In light of the theory that avascular 
microenvironments lacking endothelium-derived Notch 
ligands also harbor GSCs, we hypothesized that the Notch 
pathway is required for self-renewal of perivascular GSCs, 
but not GSCs located in hypoxic niches.
Here, we show that nuclear NICD is found in tumor 
cells within perivascular but not hypoxic regions of human 
GBM. In contrast, CD133 (PROM1), a transmembrane 
glycoprotein that marks GSCs [4, 9, 19, 20, 44, 45], 
is expressed primarily in areas of PPN and less so in 
perivascular niches. Prospective isolation of cells with 
active Notch signaling (Notchhi) using patient-derived 
cultures bearing a fluorescent Notch reporter demonstrates 
only partial overlap and extensive segregation of Notchhi 
cells and CD133-expressing (CD133hi) GSC populations 
in vitro and in vivo in intracranial xenograft tumors.. 
These cell populations occupy discreet niches in tumor 
xenografts, similar to patient tumors, and demonstrate 
distinct metabolic, transcriptional and differentiation 
profiles. Notchhi cells not only reside in perivascular 
niches, but also contribute pericyte lineages to their 
vascular microenvironment via a broader multipotency 
profile compared to CD133hi cells. We demonstrate that 
Notchhi cells are vulnerable to hypoxia due to inability to 
entrain anaerobic glycolysis, as opposed to CD133hi cells. 
Ectopic activation of Notch signaling in CD133hi cells is 
sufficient to confer vulnerability to hypoxia and reprogram 
metabolism away from anaerobic glycolysis.
Our findings indicate Notch signaling is 
heterogeneously activated within the GSC population 
and regulates metabolic adaptations to the local 
microenvironment. Our model provides a mechanistic 
understanding of intratumoral GSC heterogeneity, as 
well as a platform for elucidating microenvironmental 
regulation of stem cell behavior.
RESULTS
Notch signaling is activated in perivascular niches 
but not hypoxic areas of human GBM
To determine the spatial profile of Notch pathway 
activation in GBM, we stained 9 formalin-fixed paraffin-
embedded (FFPE) human GBM biospecimens for Notch1 
Intracellular Domain (NICD1) (Supplementary Table 1). 
All 9 biospecimens were classified as GBM based on H&E 
staining (Figure 1ai). Nuclear NICD1 was detected in 
perivascular areas (Figure 1aii, top panel), but was absent 
in regions of PPN (4/9 biospecimens with areas of PPN; 
5 biospecimens did not show PPN) (Figure 1aii, bottom 
panel; Supplementary Figure 1a). 
Immunofluorescence analysis indicated CD133 
localizes to both perivascular and avascular areas in 
human GBM, as in previous reports [19, 20] (Figure 
1aiii). Unlike NICD1, CD133 was consistently found in 
PPN areas in each biospecimen (Supplementary Figure 
1b). Given that Notch signaling and CD133 expression 
showed differential localization and both have been linked 
with GSCs, we hypothesized expression of these markers 
identifies distinct GSC populations.
Prospective isolation of tumor cells with Notch 
pathway activation
In order to further characterize cell populations 
identified by activation of Notch signaling and expression 
of CD133, we used patient-derived tumorsphere 
cultures (GBML8, 20, 33, 61) [7, 44, 46, 47]. Molecular 
subtyping of parental biospecimens was performed 
with DNA methylation profiling (Illumina 450K arrays) 
(Supplementary Figure 2ai) [47, 48]. The analysis 
classified GBML8 in the mesenchymal, and GBML20, 
GBML33 and GBML61 in the RTK1 (proneural) 
subtypes (Supplementary Figure 2b). Parental tumors had 
several molecular hallmarks of primary GBM, including 
trisomy 7 and loss of PTEN, CDKN2A, NF1 and RB1. 
Tumors showed microvascular proliferation and PPN. 
In addition, tumors were negative for IDH1/2 mutations 
(Supplementary Figure 2ai-2aiii). 
In these patient-derived cultures, we prospectively 
isolated cells with active canonical Notch signaling using 
a lentiviral reporter (NotchLenti) that expresses copGFP, 
a green fluorescent protein with short half-life (~2 hours) 
[49] that allows dynamic visualization of cells upon 
activation of the Notch pathway (Figure 1b) [29, 30]. The 
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Figure 1: Notch activation and CD133 cell surface expression show differential intratumoral localization in human 
GBM. a., i. H&E reveals areas of microvascular proliferation (top panel) and PPN (bottom panel) within the same human GBM 
biospecimen. a., ii. Nuclear NICD1 immunoreactivity is seen in perivascular areas but not in PPN regions. a., iii. In contrast, CD133 
immunoreactivity is seen in both microenvironments. b. Schematic of the lentiviral vector used to monitor Notch pathway activation. The 
20 bp-long Notch response element contains a consensus GTGGGAA site found in Notch transcriptional targets. c. Schematic depicting the 
approach for obtaining patient-derived primary tumorsphere cultures and orthotopic tumor xenografts after transduction with NotchLenti. 
Scattered Notch-activated (GFP+) cells (arrowheads) were observed in tumorspheres in vitro. d. Flow cytometry histograms of GBM lines 
show gradients of (i) increased GFP fluorescence after transduction with NotchLenti and (ii) CD133 immunoreactivity after incubation with 
anti-CD133 antibody (n = 3 primary cultures). e. Immunofluorescent analysis of xenograft tumors generated by GBML8 cells modified 
with NotchLenti reveals perivascular GFP staining for Notch activation. f. Quantification of the distance of GFP+ or CD133-expressing 
cells from the vasculature (i) in xenograft tumors generated with 2 patient-derived cultures already modified with NotchLenti shows that 
GFP+ cells prefer a perivascular localization. (n = 3 animals for each condition, ii: GBML8: ANOVA, F(2,8) = 16.93, P < 0.003 and iii: 
GBML20: ANOVA, F(2,8) = 6.049, P < 0.03). H&E: hematoxylin and eosin; N: necrosis; BV: Blood vessel; CMV: Cytomegalovirus; GFP: 
Green Fluorescence Protein; CD105: Endoglin; DAPI: nuclear counter stain; ns: not significant.
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reporter consists of 4 tandem Notch response elements 
attached to a minimal CMV promoter. Each response 
element contains a consensus GTGGGAA motif found in 
the promoters of the NICD target genes HES1 and HES5 
(Figure 1b). After treatment with 1 μg/ml puromycin to 
select for transduced cells, we observed scattered GFP+ 
cells in our tumorsphere cultures (Figure 1c). These 
cultures were used for further characterization (Figure 1c). 
Flow cytometric analysis of 3 primary cultures transduced 
with NotchLenti (GBML8, GBML20, GBML33) showed 
a gradient of GFP signal (Figure 1d). This flow cytometric 
profile was similar to the one we obtained with a HES5-
mCherry reporter utilizing 760 bp of the HES5 promoter 
(not shown) [29]. To define cells with GFP intensities 
higher than the negative control (parental cultures not 
transduced with NotchLenti), we used conventional gating 
with linear cutoffs in fluorescence intensity. We found that 
only a small population of cells (1.80 ± 0.06%) showed 
the highest activation of Notch signaling (Figure 1di). 
CD133 surface expression in these primary cultures was 
also represented by a gradient with variable percentages 
of CD133-positive cells (35.43 ± 19.51%) (Figure 1dii). 
To test the fidelity of the Notch reporter, we 
examined the effects of soluble Notch ligand delta-
like 4 (Dll4) or the γ-secretase inhibitor DAPT on 
the abundance of GFP+ cells, using flow cytometry. 
Figure 2: Segregation of Notchhi and CD133hi cell populations. a., i Flow cytometric analysis of an intracranial tumor xenograft 
derived from GBML8-NotchLenti cells shows the segregation of CD133 expression (CD133hi) and Notch activation (Notchhi). a., ii Flow 
cytometric analysis of cell surface CD133 and Notch activation (GFP reporter) in 3 primary cultures in vitro shows that there is only partial 
overlap between the two markers. For the analysis in a., GFP gates were drawn based on parental cultures not transduced with NotchLenti, 
and CD133 gates were based on control conditions without antibody (as shown in Supplementary Figure 2c). b. Experimental plan for 
studying Notchhi and CD133hi cells. c. FACS-sorted CD133hi, Notchhi and DP cells were compared to DN cells for CD133 (PROM1) and 
HES5 mRNA expression by qPCR. The experiment was performed on two different primary cultures transduced with NotchLenti: (i) 
GBML8, and (ii) GBML20 (n = 3 FACS experiments/primary cell line, t-tests, P < 0.05). d. After FACS isolation, cells were seeded at 
low density (10 cells/μl) and tumorsphere formation was analyzed 7 days after isolation. Only Notch-activated populations (Notchhi and 
DP) showed decreased tumorsphere formation upon pharmacological inhibition of the Notch pathway with 10 µM DAPT in 2 cultures: (i) 
GBML8: ANOVA, F(7,14) = 9.472, P < 0.0002, (ii) GBML20: ANOVA, F(1.4) = 74.98, P < 0.001) (n = 3 experiments/primary cell line). e. To 
further confirm CD133hi and Notchhi cells represent distinct populations in GBM, we performed RNA-seq from FACS isolated cells from 
GBML8 and GBML20. RNA sequencing revealed 420 genes that were differentially expressed in CD133hi and Notchhi GSCs compared to 
DN cells (P < 0.05). f. When the RNA-seq data were analyzed for known GSC markers, CD133hi and Notchhi cells showed enrichment for 
these transcripts compared to the DN population (n = 7 genes, ANOVA F(1, 6) = 7.490, P < 0.03). ns: not significant.
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We observed significant (1.9 ± 0.3-fold) upregulation 
in the percentage of GFP+ cells upon Dll4 (100 ng/
ml) treatment (Supplementary Figure 2a). Conversely, 
we found significant downregulation in the fraction 
of GFP+ cells (0.5 ± 0.1-fold) after DAPT (10 μM) 
treatment (Supplementary Figure 3a). In vitro lentiviral 
overexpression of NICD1 (NICD-OE) increased the 
mean intensity of GFP fluorescence in primary cultures 
(Supplementary Figure 3bi) and the abundance of 
GFP+ cells (Supplementary Figure 3bii). These findings 
suggested that the NotchLenti construct faithfully reports 
Notch pathway activation in GBM cells. 
We used confocal microscopy to examine the 
distribution of CD133+ and GFP+ (active Notch signaling) 
cells in orthotopic tumor xenografts generated from two 
primary GBM cultures (Figure 1e-1f). While GFP+ cells 
Figure 3: Notchhi cells reside higher in the cellular hierarchy in vivo. a. Cells were isolated with FACS and xenograft tumors 
generated were analyzed by flow cytometry and histology 6 months after injection. b., i Tumor cells were isolated from intracranial 
xenografts generated either by CD133hi or Notchhi cells (GBML8) after confirmation of tumors with MRI. b., ii-iii Flow cytometric analysis 
revealed that tumors initiated by CD133hi GSCs contained significantly lower numbers of Notchhi cells, whereas CD133 percentages did 
not significantly change between the two different types of tumors (n = 3 animals/condition, ANOVA F(1,8) = 9.7, P < 0.01). c. Confocal 
immunofluorescence analysis of tumor xenografts generated by parental (i), CD133hi (ii) and Notchhi (iii) GBML8 cells shows that tumors 
generated by Notchhi GSCs more closely resemble parental tumors than CD133hi tumors (n = 3 animals/condition).
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localized to perivascular spaces, CD133+ cells showed 
a diffuse distribution within tumors. Using quantitative 
image analysis, we analyzed the prevalence of CD133+ 
and GFP+ cells in zones defined according to the distance 
from the tumor endothelium (Figure 1fi). This analysis 
revealed that GFP+ cells had a significantly higher 
probability of residing close to endothelium than CD133+ 
cells, which had a more uniform spatial distribution 
(GBML8 and GBML20, Figure 1fii-iii). Collectively, 
these findings reproduce observations in patients’ tumors 
and suggest the CD133+ and GFP+ populations are 
distinct and occupy different niches.
Notch activation and CD133 surface expression 
mark distinct cell populations
To test the hypothesis that cells with active Notch 
signaling are distinct from CD133-expressing cells, 
we performed flow cytometric analysis of NotchLenti-
transduced GBM tumorsphere cultures (GBML8, 
GBML20 and GBML33) and tumor xenografts from 
these cells. We found in vivo segregation of the CD133-
expressing (CD133hi) cell population (17.55 ± 2.50% of all 
tumor cells) and the population of cells with active Notch 
signaling (Notchhi; 3.87 ± 0.85% of all tumor cells, n = 
4 mice implanted with NotchLenti-transduced GBML8 
cells) (Figure 2ai). In vitro flow cytometric analysis of 3 
primary cultures transduced with NotchLenti reproduced 
the segregation observed between Notchhi and CD133hi 
cells (Figure 2aii, Supplementary Figure 3c). There was 
only partial overlap between the Notchhi and CD133hi 
populations, so that only 43.64 ± 25.38% of Notchhi cells 
were CD133hi. Conversely, only 2.4 ± 0.3% of CD133hi 
cells were Notchhi. Supplementary Figure 3cii summarizes 
the cumulative statistics of all the subpopulations 
generated with respect to CD133 and Notch activation 
status: CD133hi/Notchlo (CD133hi), Notchhi/CD133lo 
(Notchhi), double positives (DP) and double negatives 
(DN). These findings suggested partial overlap between 
these two markers and largely distinct CD133hi and Notchhi 
cell populations.
To validate the segregation of CD133hi and Notchhi 
cell populations at the molecular level and to assess 
their cellular properties, we FACS-isolated CD133hi, 
Notchhi, DP and DN cells, and subjected them to further 
characterization (Figure 2b). In order to ensure that our 
results were not confounded by loss of the NotchLenti 
reporter construct, we performed PCR for the copGFP 
transgene from genomic DNA isolated from all 4 FACS-
sorted cell populations, which confirmed that the reporter 
transgene was present in the genome of all subpopulations 
(GBML8, Supplementary Figure 4a).
We performed qRT-PCR for transcripts encoding 
HES5, the principal transcriptional target of the Notch 
pathway in GBM [50], as well as the PROM1 (CD133) 
transcript, in FACS-isolated subpopulations. We observed 
significant enrichment of PROM1 transcript in CD133hi 
and DP populations, and HES5 transcript in Notchhi and 
DP populations, when compared to DN cells (GBML8: 
Figure 2ci, GBML20: Figure 2cii), providing validation 
of our experimental model. Expression of other Notch 
pathway elements, including NOTCH1, NOTCH2, HES1, 
HEY 1, DLL1, JAG1 and JAG2 showed no significant 
changes in expression levels among the 4 subpopulations 
(Supplementary Figure 4b, 4c). 
We next examined the ability of these cell 
populations to initiate tumorspheres in vitro and 
tumor xenografts in vivo. First, we FACS-isolated the 
subpopulations (CD133hi, Notchhi, DP and DN) and plated 
them in limiting dilutions (10 cells/μL) to determine 
sphere formation efficiency. All 4 populations showed 
equivalent sphere formation ability in 2 primary cultures 
tested (GBML8: Supplementary Figure 5ai, GBML20: 
Supplementary Figure 5aii). There were no differences 
in the size of the spheres (not shown). To test in vivo 
tumorigenicity, we injected FACS-isolated cells into the 
cerebrum of NOD.SCID mice (1.5 x 104 cells/animal). 
We observed tumor formation in all conditions (n = 2 
primary GBM cultures, Supplementary Figure 5b, 5d), 
suggesting the presence of tumor-initiating cells in all 
subpopulations. Notably however, while the size of 
Notchhi cell-derived tumors was not different from that of 
CD133hi tumors, it was significantly larger than the size 
of DP and DN-derived tumors (Supplementary Figure 
5c), suggesting enhanced tumorigenic potential in Notchhi 
and CD133hi cells compared to DP and DN cells. CD133hi 
and Notchhi cells produced tumor xenografts even when 
injected at even greater dilutions (1.5 x 103 cells/animal; 
Supplementary Figure 5d). 
In addition, we tested the self-renewal capacity of 
the distinct populations. Serial tumorsphere assay using 
FACS-isolated subpopulations from GBML8 revealed 
that all populations maintain their self-renewal for at 
least 3 passages (Supplementary Figure 5e). To test serial 
xenograft formation, we FACS-isolated subpopulations 
from a xenograft tumor formed from GBML20 cells. We 
observed that all of the animals injected with CD133hi and 
Notchhi cells showed tumor formation, however only 1/2 
animals showed tumor formation from DN cells (n = 3 for 
CD133hi and Notchhi and n = 2 for DN) (Supplementary 
Figure 5f). DP cells were not used for this assay. These 
findings indicate that CD133hi and Notchhi cells have 
enhanced and sustained tumorigenicity. Of note, the 
percentage of CD133hi and Notchhi cells remained stable 
over a 15-month period in vitro, indicating long-term self-
renewal (n = 3 cultures, Supplementary Figure 5g-5h). 
Previous data suggested inhibition of Notch 
signaling depletes CD133-expressing cells [6, 33]. 
However, recent reports indicated that not all CD133-
positive GBM cells are sensitive to γ-secretase inhibitors 
[51]. To explain this controversy, we tested whether 
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Figure 4: CD133hi and Notchhi GSCs have distinct angiogenic properties. a. Representative images of GBML8 xenografts show 
the contrast in vascular morphology of tumors derived from Notchhi (top panel) and CD133hi (bottom panel) cells (n = 3 animals/cell type). 
b. No significant change was observed in the number of vessels and average vascular area in xenografts generated by Notchhi or CD133hi 
cells from cultures GBML8 and GBML20 (4 20x fields/condition, n = 3 animals/cell type, t-tests, P > 0.05). c. Notchhi-initiated tumors 
contain large-caliber vessels, which are absent in CD133hi tumors (GBML8 and GBML20, n = 3 animals/cell type; Wilcoxon test, P < 
0.001). d.,e. CD133hi tumors showed reduced perfusion (Evans Blue staining) and increased hypoxia (pimonidazole staining), compared to 
tumors generated by Notchhi cells (representative images from GBML8 xenografts, n = 3 animals/condition). f. Tumors initiated by Notchhi 
and CD133hi cells do not contain hNA+ endothelium (CD105+ cells) (representative images from GBML8 xenografts, n = 3 animals/cell 
type). g. α-SMA+ pericytes envelope larger vessels in Notchhi tumors (top panel). CD133hi tumors are devoid of pericytes (representative 
images from GBML8 xenografts, n = 3 animals/cell type). h. Lineage tracing in GBML8 xenografts shows GFP+ pericytes, indicating that 
they are derived from Notchhi cells. The inset shows that CD105+ endothelium is GFP- (n = 3 animals). ns: not significant.
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inhibition of Notch signaling with the γ-secretase inhibitor 
DAPT (10 µM) differentially impairs tumorsphere 
formation in these subpopulations. Inhibition of Notch 
activation selectively inhibited tumorsphere formation in 
Notchhi and DP, but not CD133hi or DN, cells (GBML8: 
Figure 2di, GBML20: Figure 2dii). This result suggests 
tumorsphere initiation by CD133hi cells does not depend 
on Notch signaling. 
Notchhi and CD133hi have distinct transcriptional 
profiles but overlapping GSC signatures
To understand the molecular etiology of biological 
differences between Notchhi and CD133hi GSCs, we 
performed RNA-seq on FACS-isolated cells from 
GBML8 and GBML20. We identified 420 genes that were 
differentially expressed in Notchhi and CD133hi GSCs 
relative to DN cells (P < 0.05; Figure 2e, Supplementary 
Tables 2-7). Supervised hierarchical clustering based on 
these 420 genes (Supplementary Figure 6a) revealed cells 
of the same GSC subtype from different cultures clustered 
together, suggesting preserved transcriptional signatures of 
these subtypes across tumors. Unsupervised hierarchical 
clustering using the entire transcriptome produced 
similar results (Supplementary Figure 6b). Furthermore, 
Notchhi and CD133hi cells clustered more closely to 
each other than to DN cells, possibly due to shared GSC 
transcripts underrepresented in DN cells. Indeed, when 
we interrogated RNA-seq data for transcripts associated 
with GSCs such as NES, SOX2, BMI1, POU5F1, CXCR4, 
EZH2 and MET [5, 52], we found CD133hi and Notchhi 
cells upregulate this gene network relative to the DN 
population (Figure 2f). These findings suggest CD133hi 
and Notchhi possess stem-like properties but differ in other 
aspects of their biology. 
We next tested whether molecular signatures of 
parental tumors, as defined by TCGA data analysis [12], 
were detected in the 4 cell populations (CD133hi, Notchhi, 
DP and DN). Supervised hierarchical clustering with 448 
genes used to subtype TCGA biospecimens in Verhaak 
et al. [12] (Supplementary Figure 6c) validated that the 
TCGA gene expression signature of parental tumors 
is preserved within the 4 subpopulations of each tumor 
(Supplementary Figure 6d). This finding suggested that 
GSC subtypes did not represent genomically distinct 
subclones within each tumor, but rather functionally 
specialized subpopulations. Furthermore, it supports the 
hypothesis that within any given GBM tumor, regardless 
of its TCGA molecular subgroup, there exist GSC 
subtypes with defined and differentially regulated gene 
networks. 
As shown in Supplementary Figure 4b, 4c, CD133hi 
and Notchhi cells express similar levels of NOTCH1 and 
NOTCH2 transcripts using qRT-PCR assays. This finding 
was reproduced with RNA-seq data. Furthermore, RNA-
seq did not show any difference between the two cell types 
in transcripts encoding components of the γ-secretase 
complex (PSEN1, APH1, PSENEN, NCSTN) or NICD’s 
nuclear binding partners RBPJ and MAML1-3. Overall, 
these findings suggest that the lack of Notch pathway 
activation in CD133hi cells is not due to low expression 
of the basic molecular machinery required for Notch 
signaling. 
Notchhi GSCs have broader differentiation 
potential than CD133hi GSCs
To test the cells’ differentiation potential, we 
examined the progeny of the 4 FACS-sorted populations 
7 days after isolation (GBML8 and GBML20, 
Supplementary Figure 6a-6c). While populations with 
active Notch signaling (Notchhi and DP) gave rise to 
both Notchhi and Notchlo populations in vitro, CD133hi 
cells were only able to differentiate into Notchlo 
progeny (CD133hi and DN cells). DN cells generated 
CD133hi lineages but failed to produce Notchhi progeny 
(Supplementary Figure 7a-7c). These results suggest that 
Notchhi cells have broader differentiation potential than 
CD133hi cells, which show a restricted differentiation 
program that excludes lineages with active Notch 
signaling in vitro.
To identify progeny of CD133hi and Notchhi GSCs 
in vivo, we injected FACS-sorted GBML8 cells into 
mouse brains and analyzed tumor xenografts with flow 
cytometry 6 months later (Figure 3a). After confirmation 
of tumors with MRI (Figure 3bi), we observed that tumors 
initiated by Notchhi cells contained all lineages, while 
tumors initiated by CD133hi GSCs were inefficient in 
generating Notchhi cells. The abundance of CD133hi cells 
in the two types of tumor was not different (Figure 3bii-
3biii). These findings indicated broader differentiation 
potential in Notchhi cells and suggested the Notchhi to 
CD133hi differentiation program is tightly regulated and 
predominantly unidirectional. 
To test the hypothesis that Notchhi cells reside higher 
than CD133hi cells in GBM’s cellular hierarchy by virtue 
of their broader differentiation potential, we examined 
the histology of tumor xenografts obtained by either cell 
type and compared them to parental tumors derived from 
unsorted cultures (GBML8, Figure 3ci-3ciii). Tumors 
generated by Notchhi GSCs (Figure 3ciii) showed elaborate 
vascular trees, similar to xenografts initiated by injection 
of parental cultures (Figure 3ci). In contrast, tumors 
initiated by CD133hi gave rise to a rather monotonous 
histology, characterized by a uniform network of small 
vessels (Figure 3cii). This finding supported the hypothesis 
that Notchhi GSCs have a broader differentiation potential 
than CD133hi GSCs.
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Notchhi and CD133hi cells differ in their angiogenic 
potential
The vascular phenotype of the xenografts initiated 
by Notchhi and CD133hi cells was distinct. In Notchhi-
derived tumors, we observed a combination of large and 
small diameter vessels, whereas CD133hi-initiated tumors 
were devoid of large-diameter vessels and contained a 
uniform network of smaller vessels (GBML8: Figure 
4a, GBML20: Supplementary Figure 8a). Although the 
number of vessels and cumulative vascular area did not 
differ between the two conditions (Figure 4b), a dot plot 
of the area of individual vessels demonstrated a clear 
difference in size distribution (Figure 4c). 
Figure 5: CD133hi GSCs selectively utilize anaerobic glycolysis. a. GSEA analysis of transcriptomes of CD133hi and Notchhi 
cells revealed enrichment of hypoxia-responsive genes in CD133hi GSCs. b. Heatmap showing differentially expressed genes between 
CD133hi and Notchhi cells from the same gene set as in (a). c. Fold enrichment of critical hypoxia-induced genes in the CD133hi population. 
d. Schematic representation of these genes in the glycolytic and oxidative phosphorylation pathways. e. Western blotting for HIF1α shows 
increased protein levels after 24 hours of hypoxia in 3 different GBM cultures. f. CD133hi GSCs had higher total lactate levels than Notchhi 
GSCs in normoxic conditions (n = 3 experiments/primary cell line, t-tests, P < 0.04). g. CD133hi cells had significantly lower intracellular 
pH compared to Notchhi cells in normoxia (GBML8, t-test, P < 10-12). h. After 24 hours of hypoxia, CD133hi cells were able to further 
increase lactate production compared to Notchhi cells (n = 3 experiments, GBML8: t-test, P < 0.05, GBML20: t-test, P < 0.03). NES: 
normalized enrichment score; ETC: electron transport chain.
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We then tested whether the differences in the 
morphology of the tumor vasculature correlated with 
changes in tissue oxygenation. Immunofluorescence 
analysis revealed that tumors initiated by CD133hi cells, 
but not Notchhi cells, expressed the hypoxia marker 
Carbonic Anhydrase 9 (CAIX) (Supplementary Figure 8b) 
[53]. We observed that, when animals were injected with 
pimonidazole i.p and Evans Blue i.v. before sacrificing, 
to analyze vascular perfusion and the extent of hypoxia 
in these tumors [47, 54], Notchhi-initiated tumors showed 
elevated perfusion, while CD133hi-initiated tumors 
showed less perfusion and increased hypoxia (Figure 4d, 
4e). Collectively, these findings indicate that CD133hi 
cells give rise to hypo-perfusing and hypoxic tumors, in 
contrast to Notchhi-initiated tumors.
To understand the differences in vascular 
morphology, we analyzed the extent of pericytic and 
endothelial differentiation, since previous reports indicated 
GSCs generate endothelial and pericytic lineages [32, 34, 
35]. Using confocal microscopy and immunostaining for 
human nuclear antigen (hNA) and CD105, we were unable 
to observe tumor-derived endothelial cells in either Notchhi 
or CD133hi tumors (Figure 4f). This finding suggested that 
the distinct angiogenic profiles of Notchhi and CD133hi 
GSCs are unlikely to be due to differences in endothelial 
differentiation.
The importance of Notch signaling in the generation 
of vascular pericytes has been previously demonstrated in 
GBM [32, 55]. To test whether Notchhi GSCs differentiate 
into pericytes, we compared tumor xenografts initiated by 
Notchhi and CD133hi GSCs for pericyte immunoreactivity. 
We found pericytes, identified by α-smooth muscle actin 
(α-SMA) staining, only in Notchhi tumors, where they 
surrounded larger-caliber vessels (Figure 4g, top panel). 
Figure 6: CD133hi GSCs expand in hypoxic conditions at the expense of Notchhi GSCs. a., b. Flow cytometry shows increased 
abundance of CD133hi cells after 24 hours of hypoxia in 2 of 3 cultures (GBML8 and GBML33: t-test, P < 0.02). c. The abundance of 
Notchhi GSCs significantly decreases in the same conditions (t-test, P < 0.02, n = 3 primary cultures). d. Percent of cells in apoptosis 
analyzed by TUNEL assay: (i) GBML8: ANOVA, F(1,8) = 5.57, P < 0.05; (ii) GBML20: ANOVA, F(1,8) = 10.79, P < 0.01. e. Percent Ki67+ 
cells in CD133hi and Notchhi GSCs from two different GBM cultures after 24 hours of hypoxia: (i) GBML8: ANOVA, F(1,8) = 0.047, P > 
0.05; (ii) GBML20: ANOVA, F(1,8) = 1.9, P > 0.05). f. FACS-isolated CD133hi and Notchhi cells were allowed to form tumorspheres after 
24 hours of hypoxia. Tumorsphere formation was analyzed 7 days later. Notchhi GSCs showed a significant reduction in their tumorsphere 
formation ability after hypoxia, whereas no significant change was observed in CD133hi GSCs: (i) GBML8: ANOVA, F(1,8) = 20.27, P < 
0.002; (ii) GBML20: ANOVA, F(1,8) = 56.10, P < 0.018. 
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We observed no pericyte staining in CD133hi tumors 
(Figure 4g, bottom panel). Quantitatively, 49.11 ± 6.56% 
of α-SMA+ pericytes in Notchhi tumors (GBML8) were 
tumor-derived, as determined by their co-staining for 
hNA, similar to ratios in previous literature [32]. These 
findings suggested that Notchhi GSCs may generate 
pericyte lineages in vivo, which, correlates with formation 
of large-caliber tumor vessels.
To test the hypothesis that pericytes represent 
progeny of Notchhi GSCs, we used a tamoxifen-inducible 
lineage tracing system (NotchLineage) in GBML8, 
where CreERT2 expression is driven by the same Notch-
responsive promoter we used for our NotchLenti reporter 
constructs (Supplementary Figure 8ci) [56]. In this 
system, induction with tamoxifen causes CreERT2, which 
is specifically expressed in Notchhi GSCs, to catalyze 
recombination of the reporter construct, leading to deletion 
of DsRed and expression of GFP in progeny of Notchhi 
GSCs. One month after tamoxifen induction, we found 
clones of GFP+ cells within DsRed+ tumor xenografts 
(Supplementary Figure 8cii). Confocal microscopic 
analysis of GFP+ cells indicated that the pericyte marker 
α-SMA overlapped with GFP expression, whereas 
endothelial cells were GFP- (Figure 4h). 
These results suggest Notchhi cells are multipotent 
and give rise to tumor pericytes, as well as CD133hi 
lineages. In contrast, CD133hi cells have a restricted 
differentiation program and do not generate Notchhi cells 
or pericytes. Tumors initiated by CD133hi cells do not 
exhibit the complex vascular pattern that characterizes 
parental and Notchhi GSC-derived tumors. The pericytic 
transdifferentiation of the Notchhi cells correlates with 
increased tumor vascularity, perfusion and oxygenation, 
consistent with previous reports [55]. 
CD133hi GSCs expand in hypoxia by selective 
utilization of anaerobic glycolysis
Our observations raise the possibility that CD133hi 
cells and Notchhi cells may entrain distinct metabolic 
adaptations to their local microenvironments. To 
identify transcriptional networks unique to CD133hi and 
Notchhi cells that may underlie metabolic differences, 
we performed unbiased Gene Set Enrichment Analysis 
(GSEA) [57] on the complete gene lists in the 2 cell types. 
Gene sets upregulated by hypoxia were significantly 
enriched in CD133hi cells (Figure 5a, 5b; Supplementary 
Table 8). This set of genes included the key glycolytic 
enzymes hexokinase 2 (HK2), phosphoglycerate kinase 
(PGK1), and enolase 2 (ENO2); but also pyruvate 
dehydrogenase kinase (PDK1) and NADH dehydrogenase 
1 alpha subcomplex subunit 4 like 2 (NDUFA4L2), 
which suppress oxidative phosphorylation (Figure 5c, 
5d) [58-61]. Similarly, analysis of genes differentially 
expressed between CD133hi and Notchhi cells (P < 0.1) 
(Supplementary Table S9) with GSEA also showed 
enrichment of hypoxia-related gene sets (Supplementary 
Table 10a, 10b). Furthermore, analysis of these 
differentially expressed genes with DAVID [62] revealed 
that 7 out of the top 10 gene ontology (GO) terms were 
related to glycolysis and cellular metabolism (P < 0.01, 
Table S8b). These genes were differentially expressed 
despite CD133hi and Notchhi cells having been cultured 
under identical normoxic (20% O2) conditions prior to 
RNA isolation. 
The localization of CD133hi cells in hypoxic 
microenvironments, increased hypoxia and decreased 
perfusion in CD133hi-initiated tumors, and the upregulation 
of a hypoxic transcriptional profile suggested that CD133hi 
cells preferentially utilize anaerobic glycolysis (Figure 
5d). To test this hypothesis, we measured lactate levels 
in FACS-isolated CD133hi and Notchhi cells in normoxic 
vs. hypoxic conditions. We used western blotting against 
HIF1α to show stabilization of the protein upon hypoxia, 
confirming that the low oxygen treatment was effective 
(Figure 5e). In normoxia, CD133hi cells had 27.5 ± 7.6% 
higher lactate levels when compared to Notchhi cells 
(Figure 5f). CD133hi cells also showed significantly lower 
intracellular pH than Notchhi cells [63], consistent with 
acidification related to lactate production (Figure 5g). 
When we subjected CD133hi and Notchhi cells to hypoxia 
(1% O2) for 24 hours, CD133hi cells specifically turned on 
anaerobic glycolysis even more, manifested as increased 
lactate levels, as opposed to Notchhi cells, which failed to 
do so (Figure 5h). 
To test whether the ability of CD133hi cells to utilize 
anaerobic glycolysis bestowed upon them a selective 
growth advantage at the expense of Notchhi cells, we 
subjected primary cultures modified with the NotchLenti 
reporter to hypoxia for 24 hours. We observed that the 
percentage of CD133hi cells increased significantly in 2/3 
cultures (Figure 6a,b), consistent with prior observations 
[24]. GBML20, which did not show a significant increase, 
already had very high levels of CD133hi cells ( > 80%; 
Figure 6a, 6b). Conversely, Notchhi percentages were 
significantly lower in all samples after 24 hours in hypoxia 
(Figure 6c). To identify the mechanism of this observation, 
we interrogated the apoptotic and proliferative rates in the 
FACS-isolated subpopulations upon hypoxia (Figure 6d, 
6e). TUNEL assay indicated that hypoxia dramatically 
increased apoptosis in Notchhi but not CD133hi cells 
(Figure 6di-6dii, Supplementary Figure 9a). We did not 
observe any significant change in the proliferation rate, 
as assayed by Ki67 immunostaining, after 24 hours of 
hypoxia (Figure 6ei-6eii, Supplementary Figure 9b). 
We next tested the in vitro tumorsphere formation 
ability of FACS-isolated CD133hi and Notchhi cells under 
normoxia and hypoxia. CD133hi cells showed equivalent 
sphere-formation efficiency in the two conditions. 
However, Notchhi GSCs demonstrated a significant 
reduction in tumorsphere formation in hypoxia (GBML8: 
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Figure 6fi, GBML20: Figure 6fii). These findings suggest 
that hypoxia permits tumor growth driven by CD133hi 
GSCs, which are transcriptionally primed for anaerobic 
glycolysis. However, Notchhi GSCs undergo apoptosis and, 
therefore, cannot contribute to tumor growth in hypoxic 
regions, consistent with their preferential localization to 
perivascular areas.
Ectopic expression of NICD1 in CD133hi cells 
suppresses anaerobic glycolysis and reduces 
tolerance to hypoxia
To test the hypothesis that Notch signaling regulates 
GBM cells’ response to hypoxia and their metabolism, we 
ectopically expressed NICD1 in FACS-isolated CD133hi 
cells using a lentiviral vector, NICD-OE, which allowed 
identification of transduced cells by mCherry fluorescence 
(Figure 7a). After 7 days, mCherry+ cells were FACS-
isolated and subjected to further characterization (Figure 
7a, 7b). NICD-OE led to significant upregulation of the 
Notch transcriptional target HES5 mRNA compared to 
mCherry control virus (6.25 ± 0.76 -fold), confirming 
ectopic activation of Notch signaling (GBML8, GBML20, 
GBML61; Figure 7c). When we compared lactate levels 
in cells transduced with NICD-OE vs. control cells, we 
observed significant reduction under both normoxia (0.61 
± 0.05 -fold of control, Figure 7d) and hypoxia (0.62 ± 
0.14 -fold of control, Figure 7e). 
To analyze the effects of ectopic Notch activation 
on tumorsphere formation, we plated freshly isolated 
mCherry+ cells in limiting dilutions (10 cells/μL), 
subjected the cells to 24 hours of hypoxia and analyzed 
sphere formation 7 days later. We found that NICD-OE led 
Figure 7: Ectopic Notch activation reprograms metabolism. a. Schematic representation of the lentiviral constructs used for 
ectopic activation of the Notch pathway (NICD-OE) or the control vector (mCherry) and the experimental plan. b. Representative FACS 
plot from GBML8 cells that were infected with either NICD-OE or mCherry virus, showing transduction efficiency. c. FACS-isolated 
mCherry+ cells from GBML8, GBML20 and GBML61 cultures showed increased HES5 transcript in the NICD-OE condition (n = 3 
primary cultures, t-test, P < 0.02). d., e. Lactate level measurements in FACS-isolated mCherry+ cells after 24 hours of (d). normoxia or (e) 
hypoxia. NICD-OE led to significant downregulation in lactate levels in 3 primary cultures: (d) t-test, P < 0.001; (e) t-test, P < 0.05). (f-g) 
mCherry+ cells from GBML8 and GBML20 cells transduced with NICD-OE or mCherry virus were subjected to tumorsphere formation 
assay under normoxia or hypoxia. Ectopic Notch activation led to reduced tumorsphere formation under hypoxic conditions, whereas 
mCherry control did not show any change (n = 3/condition): f. GBML8: ANOVA, F(3,8) = 6.543, P < 0.05; (g) GBML20: ANOVA, F(3,12) = 
8.256, P < 0.01. ns: not significant.
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to a significant reduction in sphere formation in hypoxia 
compared to the mCherry control virus (GBML8 and 
GBML20: Figure 7f, 7g). These assays reproduced the 
phenotype seen with native CD133hi and Notchhi GSCs 
and suggested that ectopic activation of Notch signaling 
is sufficient to reprogram the metabolic profile of CD133hi 
cells and suppress their tolerance to hypoxia.
DISCUSSION
Inter- and intra-tumoral heterogeneity in GBM 
represent major obstacles to therapy [12, 14-16]. Here, 
we provide a novel model for functional and metabolic 
intratumoral heterogeneity within GBM’s stem cell 
population. We discovered that activation of Notch 
signaling and CD133 (PROM1) cell surface expression, 
two well-characterized GSC markers, demonstrate only 
partial overlap (Notchhi/CD133hi or DP cells). Notchhi/
CD133lo (Notchhi) and CD133hi/Notchlo (CD133hi) cells, 
the non-overlapping cell populations, show profound 
functional differences reflected in their niches, metabolism 
and differentiation profiles (Figure 8). We propose that this 
heterogeneity allows GSCs to support tumor growth in a 
wide spectrum of tumor microenvironments. Our results 
are reproducible across GBM tumors with a wild-type 
IDH background, which represent the majority of adult 
GBM [12]. 
Figure 8: Schematic summarizing the role of distinct GSCs in tumor progression.
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The tumor microenvironment in GBM is highly 
variable [11, 17, 64, 65]. Previous research demonstrated 
a perivascular niche for Nestin-expressing GSCs 
[18, 66]. However, immunohistochemical studies 
have demonstrated expression of CD133 not only in 
perivascular niches, but also in hypoxic regions [19, 20], 
supporting the idea that GSCs may also populate hypoxic 
microenvironments in GBM. Indeed, hypoxia and acidic 
stress promote the GSC phenotype [19, 21-26].
Our findings provide evidence for the co-existence 
of distinct GSC phenotypes in perivascular and hypoxic 
niches of any given tumor. In our model (Figure 8), which 
precisely mirrors our findings in GBM biospecimens, 
Notchhi GSCs show a strong predilection for vascular 
niches, likely due to the presence of Notch ligands on 
endothelial cells. Notchhi GSCs are not merely passive 
residents in perivascular microenvironments, but rather 
actively help create them, by transdifferentiating into 
pericytes. This finding is supported by recent literature 
showing that NICD1 overexpression induces pericytic 
differentiation in GBM [55]. We showed that the well-
developed tumor vasculature in tumors initiated by Notchhi 
cells produces adequate blood perfusion to prevent tumor 
hypoxia, and that the relatively aerobic metabolism of 
Notchhi GSCs is precisely tuned to this microenvironment. 
Finally, we demonstrated that activation of Notch 
signaling is sufficient for metabolic reprogramming of 
tumor cells by suppressing anaerobic glycolysis.
Our model also shows that CD133hi GSCs populate 
the tumor more diffusely, with reduced requirement for 
perivascular localization. This observation is consistent 
with previous demonstrations of CD133 immunoreactivity 
in both perivascular and hypoxic niches in GBM [19, 20]. 
The DP population in our study may indeed reflect this 
perivascular cell population that expresses CD133 and still 
relies on Notch signaling. However, our findings strongly 
suggest a hierarchical relationship between Notchhi and 
CD133hi cells. We postulate that, as the tumor expands 
and tumor cells move away from vessels, Notchhi GSCs 
generate DP and, subsequently, CD133hi lineages. We 
found that CD133hi GSCs have limited differentiation 
capacity and do not generate Notchhi cells or pericytes. 
Tumors initiated by CD133hi cells are hypoxic due to 
underdeveloped vasculature and reduced blood perfusion. 
To adapt to this hypoxic microenvironment, CD133hi 
GSCs specifically entrain a defined transcriptional network 
that allows them to bias glucose metabolism to anaerobic 
glycolysis rather than oxidative phosphorylation. While 
CD133hi cells thrive in hypoxic conditions, Notchhi GSCs 
undergo apoptosis, suggesting that their preference for 
aerobic glucose metabolism mandates a perivascular 
niche. Therefore, we propose that Notchhi and CD133hi 
GSCs support tumor growth via two parallel mechanisms.
We showed that canonical Notch signaling 
suppresses anaerobic glycolysis and confers vulnerability 
to hypoxia. This is a novel function of Notch signaling 
in GBM. Previous reports suggested that hypoxia is 
associated with induction of several components of the 
Notch pathway [24, 67]. We propose that this induction 
is compensatory, in order to boost vascularization and 
tissue oxygenation by Notchhi lineages. Nonetheless, our 
data indicate a critical window of vulnerability during 
hypoxia: Notchhi cells, which drive angiogenesis, are prone 
to apoptosis due to inability to rely on anaerobic glucose 
metabolism. Future experiments will need to determine 
the reason this inherent antithesis characterizes Notch 
signaling in GBM. One interesting possibility is that 
the broad differentiation potential of Notchhi cells may 
mandate aerobic metabolism.
Previous reports suggested that blockade of Notch 
signaling depletes CD133hi cells [6, 33, 50]. However, 
GSC sensitivity to blockers of Notch signaling is inversely 
related to the level of cell surface CD133 expression 
[51] and GBM cultures can expand in the presence of 
γ-secretase inhibitors [68], suggesting Notch-independent 
growth. Our model reconciles these discrepancies. While 
Notchhi and CD133hi cells represent largely distinct 
populations, we found that multipotent Notchhi cells 
generate CD133hi lineages. The reduction in CD133hi cell 
counts after Notch inhibition can, therefore, be explained 
by depletion of the Notchhi to CD133hi differentiation 
program. The recent clinical trial with a Notch inhibitor 
demonstrated that tumors do recur despite Notch inhibition 
[50]. We explain this as tumor propagation by CD133hi 
cells, which are resistant to Notch blockade, as we and 
Tanaka et al. [51] showed, and are already present at the 
time of Notch inhibition.
Our findings cannot rule out the possibility of GSC 
types other than Notchhi and CD133hi cells. For example, 
our xenograft studies demonstrate that the DN population 
does contain cells with tumor-initiating properties. 
However, the smaller size of tumors initiated by DN cells 
suggests a relatively low frequency of tumor-initiating 
cells in this population. 
Overall, our observations suggest tumor progression 
in GBM is mediated by distinct GSCs populating vascular 
and hypoxic niches. This heterogeneity provides an escape 
mechanism for tumors treated with agents targeting a 
single subtype but not both. For example, most patients 
with GBM are resistant to anti-angiogenic therapies [2, 3, 
69], likely due to selective kill of hypoxia-vulnerable cells 
but tumor progression by cells that tolerate hypoxia [70]. 
Likewise, Notch inhibitors failed to prevent recurrence 
[50], likely due to tumor lineages that do not depend on 
the Notch pathway. Our model provides a mechanistic 
understanding of both hypoxia-vulnerable (Notchhi) 
and -resistant (CD133hi) GSC lineages. We propose 
that future treatments will need to take into account this 
heterogeneity, in order to improve patient outcomes.
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MATERIALS AND METHODS
GBM biospecimen immunostaining for NICD1
Chromogenic Immunohistochemistry was performed 
on formalin-fixed paraffin-embedded GBM tissue on a 
Discovery XT platform (Ventana Medical Systems Inc., 
Tucson, AZ) using Ventana’s reagents, unless otherwise 
noted. Six µm-thick sections were deparaffinized in xylene 
and rehydrated through graded alcohols. Heat induced 
antigen retrieval was performed in a BioCare Decloaking 
Chamber in Tris-EDTA buffer for 20 minutes at 120oC and 
17 PSI and incubated in 3% hydrogen peroxide for 4 min. 
NICD1 antibody (1:100, Abcam, ab8925) was incubated 
for 3 hours and detected using anti-rabbit horseradish 
peroxidase multimer (OmniMap). Immune complexes 
were visualized with 3,3’-diaminobenzidene (DAB) and 
enhanced with copper sulfate (ChromoMap). Slides were 
counterstained with hematoxylin, dehydrated and mounted 
with permanent media. 
Primary tumor cultures
We followed a protocol approved by NYU 
Langone Medical Center’s Institutional Review Board 
(IRB) to procure fresh tumor tissue from consented 
patients undergoing surgery for resection of GBM 
(IRB# S12-01130). Primary human GBM cultures were 
obtained as previously described [44, 46, 47]. Four 
primary GBM cultures were used for the experiments 
described here (GBML8, GBML20 and GBML33 were 
used for NotchLenti experiments; GBML8, GBML20 
and GBML61 were used for NICD-OE experiments)
(Supplementary Figure 1). DNA was extracted from 
formalin-fixed paraffin embedded tissue and analyzed 
using Infinium 450k DNA methylation array, as described 
previously [47]. Tumors were classified according to their 
methylation profiles [48].
Quantification of distance of cells from the 
vasculature
ImageJ was used for estimating the distance 
of tumor cells from the vasculature. Three μm-thick 
optical sections from confocal z-stacks were obtained. 
Vasculature was identified using CD105 immunostaining. 
To obtain the number of vessels and vascular area, images 
were thresholded (Otsu Thresholding, ImageJ) using 
tissue not treated with primary antibody as negative 
control, and converted to binary format. Vessels > 10 
μm in length were counted. An average of 4 fields were 
calculated for each animal. In order to quantify the 
distance of cells from the vasculature, blood vessels were 
defined as above. Three regions of interest (ROIs) were 
defined for each image: promixal (0-15 μm from blood 
vessels), distal (15-30 μm) and outer ( > 15 μm). GFP and 
CD133 immunofluorescence was identified in each ROI. 
The estimate of number of cells/ROI was calculated by 
dividing the total GFP+ or CD133hi positive area by the 
estimated average area of a cell (86.2 ± 9.7 µm2). 
Plasmids and constructs
NotchLenti reporter construct (pGreenFire) was 
obtained from Systems Biosciences. The NotchLenti-
mCherry reporter was constructed by swapping 
the copGFP cassette with a mCherry cassette. The 
NotchLineage system was generated using two lentiviral 
constructs. The CreERT2 cassette and reporter construct 
were kind gifts of Dr. Philippe Ravassard (INSERM, 
France) [56]. CreERT2 was subcloned into the pGreenFire 
construct in place of copGFP. A loxP-DsRed-STOP-loxP-
GFP lentiviral construct was used as the reporter for the 
NotchLineage experiments (Supplementary Figure 7ci). 
The lentiviral vector overexpressing NICD1 was generated 
by cloning the NICD coding frame into pLVX-mCherryN1 
(Clontech), into the puromycin cassette. NICD1 plasmid 
which the subcloning was done was a kind gift of Dr. 
Iannis Aifantis (NYU School of Medicine).
Lentivirus production
Lentiviruses were generated in Lenti-X 293 
HEK (Clontech) producer cells after lipofection 
(Lipofectamine-2000, Life Technologies) with a 
combination of: transfer plasmid, encoding the viral 
genome; packaging plasmids (ViraPower Lentiviral 
expression systems, Life Technologies), encoding 
structural and enzymatic components of viral particles; 
and envelope plasmids, encoding viral envelope proteins. 
Lenti-X 293 HEK cells were cultured in Dulbecco’s 
Minimal Essential Media (DMEM, Life Technologies) 
supplemented with 10% FBS and non-essential amino 
acids. Lentiviral supernatant was collected at day 2 and 3 
after transfection, filtered (0.45 μm filter) and concentrated 
with ultracentrifugation (28,000g for 3 hours at 4°C) 
using a 4% sucrose/PBS cushion. After centrifugation, 
the supernatant was discarded and viral pellets were 
resuspended in Opti-MEM medium, aliquoted and stored 
at -80°C. Titers were determined by flow cytometry or 
qPCR-based assays (ABM).
Viral transduction
Primary GBM tumorsphere cultures were 
dissociated with Accutase (Innovative Cell Technologies). 
Cells (300 cells/μl) were incubated at 37°C overnight 
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with lentivirus at a multiplicity of infection (MOI) of 5. 
Protamine sulfate (4 μg/mL) was added to facilitate viral 
transduction. Three days after transduction, transduced 
cells were selected with appropriate antibiotics. In the case 
of NotchLenti, selection with 1 μg/mL puromycin (Life 
Technologies) was performed for 5-7 days.
Animals and stereotactic injections into mouse 
brain
Mice were housed within NYU Langone Medical 
Center’s Animal Facilities. All procedures were performed 
according to our IACUC-approved protocol (IACUC# 
120310-03). 6-8 week old NOD.SCID male mice 
(Jackson Laboratory, NOD.CB17-Prkdcscid/J, 001303) 
were anesthetized with i.p. injection of ketamine/xylazine 
(10 mg/kg and 100 mg/kg, respectively). They were then 
mounted on a stereotactic frame (Harvard Apparatus). 
A midline skin incision was made. A high-speed drill 
was used to drill a small hole in the calvaria 2 mm off 
the midline and 2 mm anterior to coronal suture. Five μl 
of a suspension of human GBM cells (100,000 cells/μl, 
unless otherwise noted) were injected through a Hamilton 
syringe (1 μl/min, Harvard apparatus, needle pump) into 
the frontal lobe through the drilled hole. The injection 
needle was left in place for an additional 5 minutes after 
the injection was completed to prevent backflow. The 
skin incision was sutured and animals were monitored 
throughout the recovery period.
Small animal MRI
Tumor formation was analyzed 1.5 months (unless 
otherwise noted) after injection of tumor cells into the 
brains of NOD.SCID mice. An MRI device bearing a 
7-Tesla horizontal bore Bruker magnet (ID = 300mm with 
zero boil off technology) in the Small Animal Imaging 
Core Facility at NYU School of Medicine was used for 
imaging. Prior to imaging animals were anesthetized with 
isoflurane gas. Stacked images were processed using 
ImageJ software. Tumor volumes were calculated with 
Amira Software.
Lineage tracing
GBM cells were transduced with the lentiviral 
NotchLineage system (Supplementary Figure 7ci). 
FACS-isolated DsRed+ cells were infected with a second 
lentivirus containing the driver construct. Transduced 
cells were selected with puromycin (1 μg/ml) for 7 days. 
Intracranial xenograft tumors were generated. Upon 
confirmation of tumors with MRI, two pulses of i.p. 
tamoxifen (150 mg/kg) were administered on sequential 
days. Animals were sacrificed 1 month after tamoxifen 
induction and immunofluorescence staining was 
performed.
Flow cytometry
For flow cytometric analysis, cells were dissociated 
with Accutase. CD133 staining was performed with 
fluorophore-conjugated AC133 antibody (Miltenyi), which 
recognizes the CD133/1 epitope. The LSRII analyzer (BD 
Biosciences) was used for flow cytometric measurements. 
For fluorescence-assisted cell sorting (FACS), a FACSAria 
cell sorter (BD Biosciences) was used with assistance 
from the NYU Langone Medical Center’s Cytometry and 
Cell Sorting Core Facility staff.
qRT-PCR expression analysis
Lysates and cDNA were prepared from 10,000 
FACS-isolated cells using TaqMan Gene expression Cells-
to-Ct kit using the manufacturer’s protocol (Ambion, Life 
Technologies). Taqman gene expression probes against 
PROM1 (CD133), NOTCH1, NOTCH2, HES1, HES5, 
HEY1, DLL1, JAG1 AND JAG2 (Supplementary Table 
11a) (Ambion, Life Technologies) were used to analyze 
changes in gene expression with qRT-PCR (Applied 
Biosystems, StepOne Real-time PCR System). Fold 
changes in expression were calculated using the ΔΔCt 
method. The HPRT1 gene was used to normalize results. 
Genomic DNA isolation and genomic PCR
Genomic DNA was isolated from 50,000 FACS-
isolated cells using the DNeasy Blood and Tissue Kit 
(Qiagen). Genomic DNA (100 ng) was used in a nested-
PCR to amplify copGFP DNA with the GoTaq DNA 
Polymerase kit (Promega) (Supplementary Table 11b). 
pGreenFire plasmid DNA was used as a positive control. 
PCR products were analyzed with 1.2% agarose gel 
electrophoresis.
Immunofluorescence staining and microscopic 
analysis
When the experimental end-point was reached, 
animals were anesthetized with Ketamine/Xylazine (10 
mg/kg and 100 mg/kg, respectively) and systemically 
perfused with first Phosphate-buffered Saline (PBS) 
and then 4% paraformaldehyde. Isolated brain tissue 
was mounted in OCT (Tissue-Tek) and 30 μm-thick 
frozen sections were obtained using a cryostat (Leica). 
Sections were blocked with 10% (w/v) BSA (Sigma), 
0.1% Triton X-100 (Sigma) in PBS for 2 hours at room 
temperature. The primary antibodies and the dilutions used 
for immunostaining are summarized in Supplementary 
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Table 12. Staining was performed in blocking solution 
for 18 hours at 4°C. Alexa488, Alexa555 and Alexa647 - 
conjugated secondary antibodies were used for fluorescent 
labeling (Life Technologies). Nuclear chromatin was 
counterstained with DAPI (Sigma). Epifluorescence 
microscopy was performed on an Eclipse E800 fluorescent 
microscope (Nikon). For confocal imaging, 30 μm z-stacks 
were obtained with an LSM700 confocal microscope 
(Zeiss). Image analyses were performed on ImageJ and 
Adobe Photoshop.
For apoptosis analysis, Click-iT Alexa Fluor 647 
imaging assay (Life Technologies) was used according to 
the manufacturer’s protocol.
RNA isolation, library preparation, RNA-
sequencing and bioinformatics
RNA was isolated from 30,000 FACS-isolated 
GBM cells using mirRNeasy Micro RNA isolation kit 
(Qiagen). RNA-Seq libraries were prepared using the 
Epicentre (Illumina) TotalScript RNA-Seq kit, starting 
from 5 ng of DNAse I-treated total RNA, and using oligo-
(dT) as the primer for cDNA synthesis. The libraries were 
pooled equimolarly and run on a HiSeq 2500 sequencing 
system, as paired 50 nucleotide reads. We sequenced 4 
cell populations (CD133hi, Notchhi, DP and DN) from 2 
patient samples (GBML8 in duplicates; and GBML20). A 
total of two flow cells were used. GBML8 samples (4 cell 
populations in duplicates) were run in one flow cell; and 
GBML20 samples (4 cell populations) samples were run 
in another. Sequencing results were de-multiplexed and 
converted to FASTQ format using Illumina Bcl2FastQ 
software. Paired-end reads were aligned to the human 
genome (build hg19/GRCh37) using the splice-aware 
STAR aligner [71]. PCR duplicates were removed 
using the Picard toolkit (http://broadinstitute.github.io/
picard). HTSeq package was utilized to generate counts 
for each gene based on how many aligned reads overlap 
its exons [72]. On average we obtained 116,558,873 ± 
10,631,963 reads. The lowest number of reads obtained 
was 83,887,138 and the highest was 158,844,383. These 
counts were then used to test for differential expression 
using negative binomial generalized linear models 
implemented by the DESeq2 R package [72]. For 
cumulative data analysis, GBML8 biological duplicates 
were first averaged. Then, that average was averaged with 
GBML20 data.
Gene set enrichment analysis (GSEA [57], http://
software.broadinstitute.org/gsea/, Broad Institute) was 
performed on complete transcriptomes from CD133hi and 
Notchhi cells with genes pre-ranked by fold change, as 
well as on differentially expressed genes. Gene Ontology 
analysis with DAVID [62] (https://david.ncifcrf.gov, NIH) 
was performed on differentially expressed genes. RNA-
seq and GSEA data and analyses are accessible through 
GEO accession number GSE99180.
Western blotting
GBM cells were lysed in Lysis Buffer (150 
mM NaCl, 50 mM Tris pH 7.4, 1 mM EDTA, 0.1% 
Triton-X100, 10% glycerol) supplemented with complete 
protease inhibitor cocktail (Roche). Lysates were 
centrifuged to remove debris and the supernatant was 
quantified using the Bradford assay. The supernatant 
was separated on an SDS-PAGE gel and transferred to 
a nitrocellulose membrane (Biorad). The membrane was 
probed with the following primary antibodies: anti-Hif1α 
(Bethyl Laboratories); and anti-β-Actin (Santa Cruz 
Biotechnology). Signal was detected with appropriate 
HRP-conjugated secondary antibodies (Life Technologies) 
suited for chemiluminescence (Thermo Scientific). 
24-hour hypoxia treatment
Cells were treated with hypoxic gas mixture (1% O2, 
5%CO2, balanced with N2) for 24 hours at 37°C using a 
hypoxia chamber (Stem Cell Technologies).
Lactate and intracellular pH measurements
Extracellular and intracellular lactate from cell 
culture medium and cell lysates, respectively, was 
measured with a colorimetric assay (Eton Bioscience). For 
pH recordings, FACS-isolated GBM cells were plated onto 
laminin-coated coverslips and left to settle for 1-2 hours 
before recording. Coverslips with attached cells served as 
the floor of a submersion chamber mounted on the stage 
of an Olympus IX-73 inverted microscope equipped for 
epifluorescence. The cells were loaded with pH-sensitive 
fluorophore BCECF (2′,7′-bis-(2-carboxyethyl)-5-(and-
6)-carboxyfluorescein) by incubation with 2 μM of the 
acetoxy-methylester (Life Technologies, CA) for 10 min 
at room temperature. During the experiment the cells 
were perfused at the rate of 2 ml/min with warmed (32°C) 
standard bicarbonate-buffered saline containing (in mM): 
124 NaCl, 26 NaHCO3, 3.0 KCl, 1.0 NaH2PO4, 2.0 CaCl2, 
1.5 MgCl2, and 10 glucose. Solution was gassed with 95% 
O2 and 5% CO2 and had a nominal pH of 7.4. A 75 W 
xenon lamp and a monochromator provided alternate 490 
and 440 nm fluorescence excitation. For each excitation 
wavelength, the respective emissions above 535 nm 
(F490 and F440, respectively) were collected via a 40x 
oil-immersion objective and an intensified CCD camera. 
Averaged fluorescence from regions of interest around 
single cells was imaged using ImageMaster software 
(Photon Technology International). The F490:F440 
ratios were converted to pHi (intracellular pH) using the 
nigericin single point technique, applying a HEPES-
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buffered calibration solution (150 mM K+ and 3 μM 
nigericin, pH 7.0) at the end of each experiment [20]. 
Data were referenced to a calibration curve previously 
constructed using nigericin-150 mM K+ solutions buffered 
with PIPES or HEPES over the pH range of 6.0-8.0.
Statistical analysis
Statistical comparisons included Student’s unpaired 
two-tailed t-test; one-way and two-way analysis of 
variance (ANOVA), followed by post hoc analysis with 
Tukey’s test; and Wilcoxon signed-rank test. Statistical 
significance cutoff was set at p < 0.05. Prism (GraphPad) 
and SPSS software (IBM) were used for statistical 
analyses. Population statistics were represented as mean ± 
standard error (SE) of the mean. Number of experiments 
and the specimens used were clarified in the figure legends 
for each experiment. 
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